Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia

Blood

Volumn 124, Issue 26, 2014, Pages 3932-3938

  Orgel, Etan ^a,b,c   Tucci, Jonathan ^a   Alhushki, Waseem ^d   Malvar, Jemily ^a   Sposto, Richard ^a,c   Fu, Cecilia H ^a,c   Freyer, David R ^a,c   Abdel Azim, Hisham ^a,c   Mittelman, Steven D ^a,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b MILLER CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Childrens Specialty Centers of Nevada   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DEXAMETHASONE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY MASS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHILD; CHILDHOOD B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD LEUKEMIA; CHILDHOOD OBESITY; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; TREATMENT RESPONSE; BODY WEIGHT; BONE MARROW; COHORT ANALYSIS; COMPLICATION; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; INFANT; LEUKEMIA; MORTALITY; NEOPLASM, RESIDUAL; OBESITY; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY WEIGHT; BONE MARROW; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA; MALE; NEOPLASM, RESIDUAL; OBESITY; OVERWEIGHT; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84919479608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-595389     Document Type: Article

References (54)

1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638.
2. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25(15):2063-2069.
3. Orgel E, Sposto R, Malvar J, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Clin Oncol. 2014;32(13):1331-1337.
4. Gelelete CB, Pereira SH, Azevedo AM, et al. Overweight as a prognostic factor in children with acute lymphoblastic leukemia. Obesity (Silver Spring). 2011;19(9):1908-1911.
5. Ethier MC, Alexander S, Abla O, Green G, Lam R, Sung L. Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(9):1677-1681.
6. Withycombe JS, Post-White JE, Meza JL, et al. Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer. 2009;53(7): 1249-1254.
7. Halton JM, Atkinson SA, Barr RD. Growth and body composition in response to chemotherapy in children with acute lymphoblastic leukemia. Int J Cancer Suppl. 1998;11:81-84.
8. Borowitz MJ, Devidas M, Hunger SP, et al; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
9. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
10. Behan JW, Yun JP, Proektor MP, et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009;69(19):7867-7874.
11. Pramanik R, Sheng X, Ichihara B, Heisterkamp N, Mittelman SD. Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy. Leuk Res. 2013;37(5):503-509.
12. Ehsanipour EA, Sheng X, Behan JW, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 2013;73(10):2998-3006.
13. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
14. Mastrangelo R, Poplack D, Bleyer A, Riccardi R, Sather H, D'Angio G. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment. Med Pediatr Oncol. 1986;14(3):191-194.
15. Griggs JJ, Mangu PB, Anderson H, et al; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553-1561.
16. Hunger SP, Loh ML, Whitlock JA, et al; COG Acute Lymphoblastic Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(6):957-963.
17. Kuczmarski R, Ogden C, Grummer-Strawn L, et al. CDC Growth Charts: United States. Advance Data From Vital and Health Statistics. Vol. 314. Hyattsville, MD: National Center for Health Statistics; 2000.
18. Weir EG, Cowan K, LeBeau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. Leukemia. 1999;13(4):558-567.
19. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom. 2005;68(1):18-24.
20. Veltroni M, De Zen L, Sanzari MC, et al; I-BFM-ALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003;88(11):1245-1252.
21. DiGiuseppe JA, Fuller SG, Borowitz MJ. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection. Cytometry B Clin Cytom. 2009;76(2):150-155.
22. Borowitz MJ, Pullen DJ, Shuster JJ, et al; Children's Oncology Group study. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia. 2003;17(8):1566-1572.
23. Cox D, Snell E. Analysis of Binary Data, 2nd ed. New York, NY: Chapman and Hall/CRC Press; 1989.
24. Cox D, Oakes D. Analysis of Survival Data. New York, NY: Chapman and Hall/CRC Press; 1984.
25. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; 2009.
26. R Development Core Team. 2012. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. ISBN 3-900051-07-0, http://www.R-project.org/.
27. Eaton DK, Kann L, Kinchen S, et al; Centers for Disease Control and Prevention. Youth Risk Behavior Surveillance - United States 2009: Surveillance Summaries. MMWR Surveill Summ. 2010;59(5):1-142.
28. Baillargeon J, Langevin AM, Lewis M, et al. Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2006;28(9): 575-578.
29. Rimmer JH, Yamaki K, Lowry BM, Wang E, Vogel LC. Obesity and obesity-related secondary conditions in adolescents with intellectual/developmental disabilities. J Intellect Disabil Res. 2010;54(9):787-794.
30. Hijiya N, Panetta JC, Zhou Y, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006;108(13):3997-4002.
31. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6(8):1321-1327.
32. Dunn TE, Ludwig EA, Slaughter RL, Camara DS, Jusko WJ. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther. 1991;49(5):536-549.
33. Zuccaro P, Guandalini S, Pacifici R, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit. 1991;13(1):37-41.
34. Chen J. Multiple signal pathways in obesityassociated cancer. Obes Rev. 2011;12(12):1063-1070.
35. Hino M, Nakao T, Yamane T, Ohta K, Takubo T, Tatsumi N. Leptin receptor and leukemia. Leuk Lymphoma. 2000;36(5-6):457-461.
36. Yun JP, Behan JW, Heisterkamp N, et al. Dietinduced obesity accelerates acute lymphoblastic leukemia progression in two murine models. Cancer Prev Res (Phila). 2010;3(10):1259-1264.
37. L Newton A, J Hanks L, Davis M, Casazza K. The relationships among total body fat, bone mineral content and bone marrow adipose tissue in earlypubertal girls. Bonekey Rep. 2013;2:315.
38. Di Iorgi N, Mittelman SD, Gilsanz V. Differential effect of marrow adiposity and visceral and subcutaneous fat on cardiovascular risk in young, healthy adults. Int J Obes (Lond). 2008;32(12):1854-1860.
39. Castillo JJ, Reagan JL, Ingham RR, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36(7):868-875.
40. Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. Cancer. 2013;119(23):4162-4169.
41. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293(2):203-211.
42. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2012;119(1):49-54.
43. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-1669.
44. Gaynon PS, Angiolillo AL, Carroll WL, et al; Children's Oncology Group. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010;24(2):285-297.
45. Schultz KR, Pullen DJ, Sather HN, et al. Riskand response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3):926-935.
46. Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clin Pediatr (Phila). 2009;48(6):601-608.
47. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515-5523.
48. Strauss RS, Pollack HA. Epidemic increase in childhood overweight, 1986-1998. JAMA. 2001;286(22):2845-2848.
49. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002;100(6):1957-1964.
50. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2012;30(17):2094-2101.
51. Cario G, Zimmermann M, Romey R, et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood. 2010;115(26):5393-5397.
52. Aldrich MC, Zhang L, Wiemels JL, et al. Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev. 2006;15(3):578-581.
53. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321.
54. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood. 2012;119(15):3512-3522.